Impact of cytogenetic and molecular prognostic markers on the clinical management of chronic lymphocytic leukemia

Haematologica

Volumn 93, Issue 1, 2008, Pages 14-19

  Hauswirth, Alexander W ^a   Jäger, Ulrich ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ALEMTUZUMAB; FLAVOPIRIDOL; FLUDARABINE; MOLECULAR MARKER; PENTOSTATIN; RITUXIMAB; WORTMANNIN;

CHRONIC LYMPHATIC LEUKEMIA; CYTOGENETICS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENE MUTATION; HEREDITY; HUMAN; IN VITRO STUDY; MINIMAL RESIDUAL DISEASE; PHARMACOGENOMICS; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SHORT SURVEY;

CPG ISLANDS; CYTOGENETIC ANALYSIS; DISEASE-FREE SURVIVAL; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPING; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MEDICAL ONCOLOGY; MODELS, GENETIC; PHARMACOGENETICS; PROGNOSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 38549137390     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.12319     Document Type: Short Survey

References (85)

1. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood 1975;46:219-34.
2. Binet JL, Lepoprier M, Dighiero G, Charron D, D'Athis P, Vaugier G, et al. A clinical staging system for chronic lymphocytic leukemia: prognostic significance. Cancer 1977;40: 855-64.
3. Rozman C, Montserrat E. Chronic lymphocytic leukemia. N Engl J Med 1995;333:1052-7.
4. Kipps TJ. Chronic lymphocytic leukemia. Curr Opin Hematol 2000;7:223-34.
5. Montserrat E. New prognostic markers in CLL. Hematology. Am Soc Hematol Educ Program 2006;279-84.
6. Mayr C, Speicher MR, Kofler DM, Buhmann R, Strehl J, Busch R, et al. Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia. Blood 2006;107:742-51.
7. Ng D, Toure O, Wei MH, Arthur DC, Abbasi F, Fontaine L, et al. Identification of a novel chromosome region, 13q21.33-q22.2, for susceptibility genes in familial chronic lymphocytic leukaemia. Blood 2007;109:916-25.
8. Goldin LR, Pfeiffer RM, Li X, Hemminki K. Familial risk of lymphoproliferative tumors in families of patients with chronic lymphocytic leukemia: results from the Swedish Family-Cancer Database. Blood 2004;104:1850-4.
9. Caporaso N, Marti GE, Goldin L. Perspectives on familial chronic lymphocytic leukemia: genes and the environment. Semin Hematol 2004;42:201-6.
10. Marti GE, Rawstron AC, Ghia P, Hillmen P, Houlston RS, Kay N, et al. The International Familial CLL Consortium. Diagnostic criteria for monoclonal B-cell lymphocytosis. Br J Haematol 2005;130:325-32.
11. Mauro FR, Giammartini E, Gentile M, Sperduti I, Valle V, Pizzuti A, et al. Clinical features and outcome of familial chronic lymphocytic leukemia. Haematologica 2006; 91: 1117-20.
12. Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE, et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukaemia. N Engl J Med 2005;352:1667-76.
13. Donner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910-6.
14. Catovsky D, Richards S, Matutes E et al. Response to therapy and survival in CLL is influenced by genetic markers. Preliminary analysis from the LRF CLL4 trial. Blood 2004; 104: [Abstract 8a].
15. Dohner H, Stilgenbauer S, James MR, Benner A, Weilguni T, Bentz M, et al. 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood 1997;89: 2516-22.
16. Oscier DG, Gardiner AC, Mould SJ, Glide S, Davis ZA, Ibbotson RE, et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 2002;100:1177-84.
17. Haslinger C, Schweifer N, Stilgenbauer S, Dohner H, Lichter P, Kraut N, et al. Microarray gene expression profiling of B-cell chronic lymphocytic leukemia subgroups defined by genomic aberrations and VH mutation status. J Clin Oncol 2004;22:3937-49.
18. Calin GA, Liu CG, Sevignani C, Ferracin M, Felli N, Dumitru CD, et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci USA 2002;99:15524-9
19. Bilban M, Heintel D, Scharl T, Woelfel T, Auer MM, Porpaczy E, et al. German CLL Study Group. Deregulated expression of fat and muscle genes in B-cell chronic lymphocytic leukemia with high lipoprotein lipase expression. Leukemia 2006;20:1080-8.
20. Stratowa C, Loffler G, Lichter P, Stilgenbauer S, Haberl P, Schweifer N, et al. CDNA microarray gene expression analysis of B-cell chronic lymphocytic leukemia proposes potential new prognostic markers involved in lymphocyte trafficking. Int J Cancer 2001;91:474-80.
21. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form or chronic lymphocytic leukemia. Blood 1999; 94:1848-54.
22. Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999;94:1840-7.
23. Hamblin TJ, Orchard JA, Ibbotson RE, Davis Z, Thomas PW, Stevenson FK, et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 2002; 99:1023-9.
24. Krober A, Seiler T, Benner A, Bullinger L, Bruckle E, Lichter P, et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 2002;100:1410-6.
25. Vasconcelos Y, Davi F, Levy V, Oppezzo P, Magnac C, Michel A, et al. Binet's staging system and VH genes are independent but complementary prognostic indicators in chronic lymphocytic leukemia. J Clin Oncol 2003;21:3928-32.
26. Thunberg U, Johnson A, Roos G, Thorn I, Tobin G, Sallstrom J, et al. CD38 expression is a poor predictor for VH gene mutational status and prognosis in chronic lymphocytic leukemia. Blood 2001;97:1892-4.
27. Stilgenbauer S, Bullinger L, Lichter P, Dohner H. German CLL Study Group (GCLLSG). Chronic lymphocytic leukemia. Genetics of chronic lymphocytic leukemia: genomic aberrations and V(H) gene mutation status in pathogenesis and clinical course. Leukemia 2002;16:993-1007.
28. Guarini A, Gaidano G, Mauro FR, Capello D, Mancini F, De Propris MS, et al. Chronic lymphocytic leukemia patients with highly stable and indolent disease show distinctive phenotypic and genotypic features. Blood 2003;102:4497-506.
29. Oscier DG, Gardiner AC, Mould SJ, Glide S, Davis ZA, Ibbotson RE, et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 2002;100:1177-84.
30. Thorselius M, Krober A, Murray F, Thunberg U, Tobin G, Buhler A, et al. Strikingly homologous immunoglobulin gene rearrangements and poor outcome in VH3-21-using chronic lymphocytic leukemia patients independent of geographic origin and mutational status. Blood 2006;107:2889-94.
31. Kienle D, Benner A, Krober A, Winkler D, Mertens D, Buhler A, et al. Distinct gene expression patterns in chronic lymphocytic leukemia defined by usage of specific VH genes. Blood 2006;107:2090-3.
32. Stamatopoulos K, Belessi C, Moreno C, Boudjograh M, Guida G, Smilevska T, et al. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations. Blood 2007;109:259-70.
33. Durig J, Nuckel H, Cremer M, Fuhrer A, Halfmeyer K, Fandrey J, et al. ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia. Leukemia 2003;17:2426-34.
34. Stamatopoulos B, Meuleman N, Haibe-Kains B, Duvillier H, Massy M, Martiat P, et al.Quantification of ZAP70 mRNA in B cells by real-time PCR is a powerful prognostic factor in chronic lymphocytic leukemia. Clin Chem 2007;53:1757-66.
35. Oppezzo P, Vasconcelos Y, Settegrana C, Geannel D, Vuillier F, Legarff-Tavernier M, et al. The LPL/ADAM29 expression ratio is a novel prognosis indicator in chronic lymphocytic leukaemia. French Cooperative Group on CLL. Blood 2005; 106:650-7.
36. Heintel D, Kienle D, Shehata M, Kröber A, Kroemer E, Schwarzinger I, et al. High expression of lipoprotein lipase in poor risk B-cell chronic lymphocytic leukaemia. CLL Study Group. Leukemia 2005;19:1216-23.
37. van't Veer MB, Brooijmans AM, Langerak AW, Verhaaf B, Goudswaard CS, Graveland WJ, et al. The predictive value of lipoprotein lipase for survival in chronic lymphocytic leukemia. Haematologica 2006;91:56-63.
38. Nückel H, Huttmann A, Klein-Hitpass L, Schroers R, Führer A, Sellmann L, et al. Lipoprotein lipase expression is a novel prognostic factor in B-cell chronic lymphocytic leukemia. Leuk Lymphoma 2006;47:1053-61.
39. Van Bockstaele F, Pede V, Janssens A, Callewaert F, Offner F, Verhasselt B, et al. Lipoprotein lipase mRNA in whole blood is a prognostic marker in B cell chronic lymphocytic leukaemia. Clin Chem 2007;53:204-12.
40. Nikitin EA, Malakho SG, Biderman BV, Baranova AV, Lorie YY, Shevelev AY, et al. Expression level of lipoprotein lipase and dystrophin genes predict survival in B-cell chronic lymphocytic leukemia. Leuk Lymphoma 2007;48:912-22.
41. Kainz B, Shehata M, Bilban M, Kienle D, Heintel D, Krömer-Holzinger E, et al. Overexpression of the paternally expressed gene 10 (PEG10) from the imprinted locus on chromosome 7q21 in high-risk B-cell chronic lymphocytic leukemia.Int J Cancer 2007;121:1984-93.
42. Oppezzo P, Vuillier F, Vasconcelos Y, Dumas G, Magnac C, Payelle-Brogard B, et al. Chronic lymphocytic leukemia B cells expressing AID display a dissociation between class switch recombination and somatic hypermutation. Blood 2003;101:4029-32.
43. McCarthy H, Wierda WG, Barron LL, Cromwell CC, Wang J, Coombes KR, et al. High expression of activation-induced cytidine deaminase (AID) and splice variants is a distinctive feature of poor prognosis chronic lymphocytic leukemia. Blood 2003;101:4903-8.
44. Albesiano E, Messmer BT, Damle RN, Allen SL, Rai KR, Chiorazzi N. Activation-induced cytidine deaminase in chronic lymphocytic leukemia B cells: expression as multiple forms in a dynamic, variably sized fraction of the clone. Blood 2003;102:3333-9.
45. Heintel D, Kroemer E, Kienle D, Schwarzinger I, Gleiss A, Schwarzmeier J, et al. High expression of activation-induced cytidine deaminase (AID) mRNA is associated with unmutated IGVH gene status and unfavourable cytogenetic aberrations in patients with chronic lymphocytic leukaemia. German CLL Study Group. Leukemia 2004;18:756-62.
46. Tchirkov A, Chaleteix C, Magnac C, Vasconcelos Y, Davi F, Michel A, et al. hTERT expression and prognosis in B-chronic lymphocytic leukemia. Ann Oncol 2004;15:1476-80.
47. Buhl AM, Jurlander J, Geisler CH, Pedersen LB, Andersen MK, Josefsson P, et al. CLLU1 expression levels predict time to initiation of therapy and overall survival in chronic lymphocytic leukemia. Eur J Haematol 2006;76:455-64.
48. Bottcher S, Ritgen M, Pott C, Bruggemann M, Raff T, Stilgenbauer S, et al. Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation. Leukemia 2004;18:1637-45.
49. Nabhan C, Coutre S, Hillmen P. Minimal residual disease in chronic lymphocytic leukaemia: is it ready for primetimeinverted ? sign Br J Haematol 2007;136:379-92.
50. Wendtner CM, Ritgen M, Schweighofer CD, Fingerle-Rowson G, Campe H, Jager G, et al. Consolidation with alemtuzumab in patients with chrome lymphocytic leukemia (CLL) in first remission - experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). The German CLL Study Group (GCLLSG). Leukemia 2004;18:1093-101.
51. Moreton P, Kennedy B, Lucas G, Leach M, Rassam SM, Haynes A, et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 2005;23:2971-9.
52. Rosenwald A, Alizadeh AA, Widhopf G, Simon R, Davis RE, Yu X, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001;194:1639-47.
53. Klein U, Tu Y, Stolovitzky GA, Mattioli M, Cattoretti G, Husson H, et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 2001;194:1625-38.
54. Vasconcelos Y, De Vos J, Vallat L, Reme T, Lalanne AI, Wanherdrick K, et al. Gene expression profiling of chronic lymphocytic leukemia can discriminate cases with stable disease and mutated Ig genes from those with progressive disease and unmutated Ig genes. The French Cooperative Group on CLL. Leukemia 2005;19:2002-5.
55. Haferlach C, Dicker F, Schnittger S, Kern W, Haferlach T. Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgV(H) status and immunophenotyping. Leukemia 2007[Epub ahead of print].
56. Fernàndez V, Jares P, Salaverria I, Giné E, Beà S, Aymerich M, et al. Gene expression profile and genomic changes in disease progression of early-stage chronic lymphocytic leukaemia. Haematologica 2007; 93:132-6.
57. Chen L, Widhopf G, Huynh L, Rassenti L, Rai KR, Weiss A, Kipps TJ. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2002;100:4609-14.
58. Wiestner A, Rosenwald A, Barry TS, Wright G, Davis RE, Henrickson SE, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003;101:4944-51.
59. Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003;348:1764-75.
60. Rai KR, Chiorazzi N. Determining the clinical course and outcome in chronic lymphocytic leukemia. N Engl J Med 2003;348:1797-9.
61. Orchard JA, Ibbotson RE, Davis Z, Wiestner A, Rosenwald A, Thomas PW, et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 2004;363:105-11.
62. Rassenti LZ Huynh L, Toy TL, Chen L, Keating MJ, Gribben JG, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004; 351:893-901.
63. Letestu R, Rawstron A, Ghia P, Villamor N, Leuven NB, Boettcher S, et al. Evaluation of ZAP-70 expression by flow cytometry in chronic lymphocytic leukemia: A multicentric international harmonization process. Cytometry B Clin Cytom 2006;70:309-14.
64. Krober A, Bloehdom J, Hafner S, Buhler A, Seiler T, Kienle D, et al. Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia. J Clin Oncol 2006;24:969-75.
65. Stilgenbauer S, Dohner H. Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N Engl J Med 2002;347:452-3
66. Lozanski G, Heerema NA, Flinn IW, Smith L, Harbison J, Webb J, et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 2004;103:3278-81.
67. Pettitt AR, Matutes E, Oscier D. Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects. Leukemia 2006; 20:1441-5.
68. Giné E, Crespo M, Muntanola A, Calpe E, Joao Gomes M, Villamor N, Montserrat E, Bosch F. Induction of Histone H1.2 cytosolic release in chronic lymphocytic leukemia cells after genotoxic and non-genotoxic treatment. Haematologica 2007; 93:75-82.
69. Byrd JC, Lin TS, Dalton JT, Wu D, Phelps MA, Fischer B, et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukaemia. Blood 2007;109:399-404.
70. Kay NE, Geyer SM, Call TG, Shanafelt TD, Zent CS, Jelinek DF, et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 2007; 109:405-11.
71. Kim DH, Jung HD, Kim JG, Lee JJ, Yang DH, Park YH, et al. FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. Blood 2006;108:2720-5.
72. Castro JE, Prada CE, Loria O, Kamal A, Chen L, Burrows FJ, et al. ZAP-70 is a novel conditional heat shock protein 90 (Hsp90) client: inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis, and impaired signaling in chronic lymphocytic leukemia. Blood 2005;106:2506-12.
73. Pallasch, Schwamb J, Schulz A, Debey S, Kofler D, Schultze Hallek M, et al. Overexpression of lipases enables specific cytotoxicity by the lipase inhibitor orlistat in chronic lymphocytic leukemia cells. ASH Annual Meeting Abstracts. Blood 2006;108:[abstract 2800].
74. Shehata M, Schnabl S, Demirtas D, Schwarzmeier JD, Hilgarth M, Duechler M, et al. Lymphoid microenvironment inhibits apoptosis in B-CLL cells: Involvement of PI3-K/AKT Pathway and PTEN. ASH Annual Meeting Abstracts. Blood 2006; 108:[abstract 1441].
75. + autologous T lymphocytes. Blood 2005;105:1566-73.
76. Matthews C, Catherwood MA, Larkin AM, Clynes M, Morris TC, Alexander HD. MDR-1, but not MDR-3 gene expression, is associated with unmutated IgVH genes and poor prognosis chromosomal aberrations in chronic lymphocytic leukemia. Leuk Lymphoma 2006;47:2308-13.
77. Rosenwald A, Chuang EY, Davis RE, Wiestner A, Alizadeh AA, Arthur DC, et al. Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response. Blood 2004;104:1428-34.
78. Montillo M, Tedeschi A, Miqueleiz S, Veronese S, Cairoli R, Intropido L, et al. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. J Clin Oncol 2006;24:2337-42.
79. Montserrat E. Treatment of chronic lymphocytic leukemia: achieving minimal residual disease-negative status as a goal. J Clin Oncol 2005;23:2884-5.
80. Ritgen M, Stilgenbauer S, von Neuhoff N, Humpe A, Bruggemann M, Pott C, et al. Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR. Blood 2004; 104:2600-2.
81. Moreno C, Villamor N, Colomer D, Esteve J, Martino R, Nomdedeu J, et al. Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia. J Clin Oncol 2005;23:3433-8.
82. Binet JL, Caligaris-Cappio F, Catovsky D, Cheson B, Davis T, Dighiero G, et al. International Workshop on Chronic Lymphocytic Leukemia (IWCLL). Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. Blood 2006;107:859-61.
83. Ghia P, Stamatopoulos K, Belessi C, Moreno C, Stilgenbauer S, Stevenson F, et al. European Research Initiative on CLL. RRIC recommendations on IGHV gene mutational status analysis in chronic lymphocytic leukemia. Leukemia 2007; 21:1-3.
84. Gowda A, Byrd JC. Use of prognostic factors in risk stratification at diagnosis and time or treatment of patients with chronic lymphocytic leukemia. Curr Opin Hematol 2006; 13:266-72.
85. Byrd JC, Gribben JG, Peterson BL, Grever MR, Lozanski G, Lucas DM, et al. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J Clin Oncol 2006;24: 437-43.